国产九价HPV疫苗最终定价公布，不到进口一半

Core Viewpoint - The launch of China's first domestically produced nine-valent HPV vaccine "Xinkening®9" at a price of 499 yuan per dose significantly undercuts the imported vaccine priced at 1300 yuan, marking the end of the "high-price era" for HPV vaccines [1] Group 1: Product Pricing and Market Impact - The domestic nine-valent HPV vaccine is priced at approximately 40% of the imported vaccine's market standard price [1] - The competitive pricing is expected to enhance the willingness of eligible women to get vaccinated, contributing to the establishment of a national immunity barrier and accelerating the goal of cervical cancer elimination [1] - The pricing strategy is projected to benefit over 100 million women in China and positively impact global cervical cancer prevention efforts [1] Group 2: Company Initiatives and Global Expansion - After the approval of the nine-valent HPV vaccine, the company is actively advancing the national bidding and procurement process as per its established plan [1] - The company is also working diligently on the WHOPQ certification process for the nine-valent HPV vaccine, leveraging its international achievements with the two-valent HPV vaccine, which has gained market access in over 20 countries and is included in the immunization programs of 8 countries [1] - The company expresses confidence in accelerating the overseas access and expansion of the nine-valent HPV vaccine through its established global network [1]